Trends for ERBB2 and Her2-Targeting Therapies in Real-World Multi-Modal Data

Time: 10:00 am
day: Day Two


  • The Tempus platform supports assessment of tumor genetics, transcriptomics, imaging and clinical outcomes across our vast US clinical network
  • Integration of multiple data modalities enables integration of Her2 status in the context of most other clinical biomarkers relevant to breast cancer
  • Transcriptomics can provide a surrogate to expand the clinical utility of Her2 outside of indications tested with IHC/FISH